Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
AstraZeneca
McKesson
Dow
Boehringer Ingelheim

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,534,092

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,534,092 protect, and when does it expire?

Patent 6,534,092 protects VIVITROL and is included in one NDA.

This patent has nineteen patent family members in eleven countries.

Summary for Patent: 6,534,092
Title: Method for preparing microparticles having a selected polymer molecular weight
Abstract:A method for preparing microparticles having a selected polymer molecular weight. The hold time and temperature of a solution containing a nucleophilic compound and a polymer having a starting molecular weight are controlled in order to control the molecular weight of the polymer in the finished microparticle product. In this manner a selected polymer molecular weight in the finished microparticle product can be achieved from a variety of starting material molecular weights.
Inventor(s): Wright; Steven G. (Madeira, OH), Rickey; Michael E. (Loveland, OH), Ramstack; J. Michael (Lebanon, OH), Lyons; Shawn L. (Cincinnati, OH), Hotz; Joyce M. (Cincinnati, OH)
Assignee: Alkermes Controlled Therapeutics, Inc. II (Cambridge, MA)
Application Number:10/073,864
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,534,092

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Alkermes VIVITROL naltrexone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 021897-001 Apr 13, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,534,092

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 399535   Start Trial
Australia 2001255465   Start Trial
Australia 5546501   Start Trial
Canada 2405787   Start Trial
Cyprus 1110403   Start Trial
Cyprus 1113082   Start Trial
Germany 60134640   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Merck
Moodys
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.